Verrica Pharmaceuticals Inc. Common Stock (VRCA)

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common war…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

76

Website

verrica.com/

Fundamentals

1-day range

$5.01$5.83

Market cap

$90.19M

P/E (trailing)

—

P/E (forward)

-3.86

EPS (trailing)

$-1.03

Dividend yield

—

Beta

1.61

Avg. volume

55.2K

Forecasts

5 analyst ratings

Verrica Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VRCA

  Verrica Pharmaceuticals Inc. Common Stock

  $5.54

  ▲ 9.27%
  Market cap $90.19MP/E —
  $3.28$9.82
• NTHI

  NeOnc Technologies Holdings Inc. Common Stock

  $4.69

  ▲ 1.74%
  Market cap $89.73MP/E —
  $3.01$12.99
• FBIO

  Fortress Biotech Inc. Common Stock

  $2.77

  ▼ 1.07%
  Market cap $91.68MP/E 0.75
  $2.18$4.53
• ALDX

  Aldeyra Therapeutics Inc. Common Stock

  $1.49

  ▼ 3.57%
  Market cap $92.29MP/E —
  $1.07$6.18
• ONCY

  Oncolytics Biotech Inc. Common Stock

  $0.8457

  ▼ 0.51%
  Market cap $92.50MP/E —
  $1.39$1.44
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $86.38MP/E —
  $6.01$17.44
• LFVN

  Lifevantage Corporation Common Stock (Delaware)

  $6.6

  ▲ 2.33%
  Market cap $83.01MP/E 14.23
  $3.9$14.28

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Verrica Pharmaceuticals Announces Completed Enrollment In COVE-2 Pivotal Phase 3 Trial Of YCANTH For Common Warts; Says Topline Data Expected In Q1 2027
  benzinga · 8/27/2026
• Verrica Pharmaceuticals Q2 Earnings Call Highlights
  Yahoo · 8/7/2026
• Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
  Yahoo · 8/6/2026
• Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
  Yahoo · 8/6/2026
• Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
  Yahoo · 8/6/2026
• Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
  Benzinga · 8/6/2026

• David Zawitz · June 5, 2026 · Grant

  171.3K
• Jayson Rieger · June 5, 2026 · Grant

  512.3K
• Eichenfield Lawrence · June 5, 2026 · Grant

  16.0K
• Nguyen Diem · June 5, 2026 · Grant

  16.0K
• Corcoran Gavin · June 5, 2026 · Grant

  16.0K
• Noah L. Rosenberg · June 5, 2026 · Grant

  233.8K
• PRYGOCKI MARK A SR · June 5, 2026 · Grant

  16.0K

Institutional Ownership

March 31, 2026

Total shares held

4.71M

Total value held

$24.92M

Institutional holders

36